Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akero Therapeutics

43.37
-0.2100-0.48%
Volume:191.41K
Turnover:8.32M
Market Cap:3.45B
PE:-11.55
High:44.73
Open:44.73
Low:42.70
Close:43.58
Loading ...

Akero Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
17 Jan

Promising Developments in Akero Therapeutics’ EFX Fuel Buy Rating with $50 Price Target

TIPRANKS
·
17 Jan

Bank of America Securities Remains a Hold on Akero Therapeutics (AKRO)

TIPRANKS
·
15 Jan

Positive Outlook for Akero Therapeutics Based on Promising Clinical Trial Developments

TIPRANKS
·
14 Jan

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 Synchrony Real-World Study Evaluating Efruxifermin (Efx) in Patients With Non-Invasively Diagnosed Mash or Masld

THOMSON REUTERS
·
13 Jan

Akero Therapeutics Inc - Data From Synchrony Real-World Study Expected in H1 2026

THOMSON REUTERS
·
13 Jan

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD

GlobeNewswire
·
13 Jan

Why Is Akero Therapeutics, Inc. (AKRO) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Insider Monkey
·
05 Dec 2024

Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference

GlobeNewswire
·
26 Nov 2024

BUZZ-Akero Therapeutics rises after Citi initiates with 'buy' rating

Reuters
·
19 Nov 2024

Citigroup Initiates Akero Therapeutics at Buy With $65 Price Target

MT Newswires Live
·
18 Nov 2024

Akero Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Nov 2024

Promising Potential of Akero Therapeutics’ Efruxifermin Highlighted by Positive Phase 2b HARMONY Study Results

TIPRANKS
·
18 Nov 2024

Akero Therapeutics (AKRO) Receives a Buy from Phillip Securities

TIPRANKS
·
18 Nov 2024

Promising Clinical Trial Results and Future Potential Justify Buy Rating for Akero Therapeutics

TIPRANKS
·
17 Nov 2024

Akero to showcase new analyses of Phase 2b HARMONY study at AASLD

TIPRANKS
·
16 Nov 2024